AnalystBook Research · Company Intelligence

Passage BIO, Inc.

PASGNasdaq

Built from Passage BIO, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score -37.71 distress zone — historically elevated failure riskWatch

Leadership changes

From Passage BIO, Inc.'s own filings, the day they're filed.

  • Thomas Kassberg · director · appointmenteff. 2024-09-10
  • Thomas Woiwode · Directors · departureeff. 2023-07-26
  • Kathleen Borthwick · President · appointmenteff. 2023-07-15

Latest filings

  • 8-K · Company announcement2026-09-03
  • 10-Q · Quarterly report2026-08-10
  • 8-K · Company announcement2026-06-24
  • 8-K · Company announcement2026-05-27
  • 8-K · Company announcement2026-05-26
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Passage BIO, Inc., every answer cited to the official filings🔒
  • The Intelligence Brief — added when Passage BIO, Inc.'s brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.